GC
KNSA icon

GMT Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

GMT Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-341,553
Closed -$5.99M – 59
2023
Q4 		$5.99M Sell
341,553
-136,300
-29% -$2.24M 0.23% 36
2023
Q3 		$8.3M Buy
477,853
+178,609
+60% +$3.01M 0.31% 46
2023
Q2 		$4.21M Buy
+299,244
New +$4.01M 0.16% 51

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GMT Capital's KNSA Position: Q1 2024 in Review

GMT Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2024, closing a stake of 341,553 shares — an estimated $5.99M sold.

GMT Capital first reported a position in KNSA in Q2 2023 and held it in 3 quarters. The position peaked at $8.3M in Q3 2023. 154 funds tracked by Wall St. Rank hold KNSA as of Q1 2024.

  • GMT Capital reported no remaining Kiniksa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • GMT Capital sold 341,553 Kiniksa Pharmaceuticals shares in Q1 2024, an estimated $5.99M.
  • GMT Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • GMT Capital's Kiniksa Pharmaceuticals position peaked at $8.3M in Q3 2023.
  • 154 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2024.

Based on GMT Capital's 13F filing for Q1 2024, filed 13 May 2024.